- Email: [email protected]
Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer
234
Citations from the Literature
resulted in slightly less additive interaction than simultaneous long-term exposure. Pretreatment with S-FU followed by a continuous exposure to MMC was as effective as the simultaneous method, as long as MMC was added within an 8-h interval. Drug schedule dependency was examined, revealing that MMC, as a single agent, is both dose and schedule dependent. The results of these in vitro studies suggest that: (I) exposure to prior chemotherapy does not induce demonstrable pleiotropic drug resistance in these ovarian cancers tested; and (2) combined S-FU and MMC show positive interactions against ovarian cancer cell lines, with optimal scheduling seeming to be long-term simultaneous exposure to both MMC and S-FU. Clirdcal assessment of ~%-CYT-103 immunoscintigraphyin ovarian cancer Surwit E.A.; Childers J.M.; Krag D.N.; Katterhagen J.G.; Gallion H.H.; Waggoner S.; Mann W.J. Jr. USA GYNECOL ONCOL 1993 48/3 (285-292) The ability of “‘In-CYT-103 immunoscintigraphy to aid in the diagnosis of patients with primary or recurrent/residual ovarian cancer was evaluated in a multicenter trial. The “‘lnlabeled irnmunoconjugate of the monoclonal antibody B72.3 was prepared using a site-specific conjugation method. A total of 103 patients received a I mg infusion of “‘In-CYT-103 and subsequently underwent surgery or biopsy. The infusion of “‘In-CYT-103 was well tolerated; only I patient experienced a modest elevation in blood pressure that was likely related to the infusion. “‘In-CYT-103 immunoscintigraphy correctly identified surgically confirmed tumor in 68% of patients with ovarian adenocarcinoma. The sensitivity of “‘InCYT-103 immunoscintigraphy was positively influenced both by the size of the tumor lesion and the tumor TAG-72 antigen expression. The overall sensitivity of “‘InXYT-103 immunoscintigraphy was greater than that of CT imaging (44%). Antibody imaging detected occult disease in 20 of 71 patients with surgically documented ovarian adenocarcinoma; 6 patients being evaluated after initial surgery and chemotherapy had an otherwise negative presurgical workup and a normal CA I25 serum level. The results of this trial also indicate that “‘In-CYT-I03 immunoscintigraphy can contribute to the medical and surgical management of some patients with ovarian cancer. The results of this trial indicate that “‘In-CYT-I03 immunoscintigraphy should be a valuable addition to the presurgical evaluation of patients with suspected persistent or recurrent ovarian cancer. Traasvaginal ultrasonographic characterization of ovarian masses by mesas of color flow-directed Doppler measurements ami a morphologicscoring system Timor-Tritsch I.E.; Lerner J.P.; Monteagudo A.; Santos R. USA AM J OBSTET GYNECOL 1993 16813I (909-913) Objective: The aim of the study was to test the hypothesis that a combination of a previously devised morphologic scoring system and color flow-directed Doppler measurements would afford better discrimination between benign and maligInt J Gynecol Obstet 43
nant ovarian masses. Study design: The scoring system and color flow-directed Doppler measurements for I I5 masses were prospectively analyzed and correlated with histopathologic surgical findings. Results: In 21 masses (18.patients) no flow was obtained. Seventy-eight masses in 70 patients were benign, and I6 masses in I2 patients were malignant. The mean total score for the benign masses was 6.7 and for the malignant masses. I I .7. The resistance index was 0.64 for the benign lesions and 0.39 for the malignant masses (range 0.2 to 0.98). The mean pulsatility index of the benign masses was I. I7 and 0.52 for the malignancies (range 0.2 to 2.6). There were no malignancies in the group with no flow obtained. The sensitivity and specificity of score alone was 94% and 87%, respectively, with a 60% positive predictive value. By means of resistance index or pulsatility index the sensitivity was 94%, the specificity 99% and the positive predictive value 94%. Conclusion: These results suggest that Doppler flow measurements alone and in conjunction with a scoring system help differentiate benign from malignant masses. Schauta-Amreichvaginal hysterectomyand Wertheim-Meigsabdominal hysterectomyin the treatment of cervical cancer: A retrospective analysis Massi G.; Savino L.; Susini T. ITA AM J OBSTET GYNECOL 1993 16813I (928-934) Objective: The aim of the current study was to determine the effectiveness of Schauta’s vaginal hysterectomy in the treatment of stage IB or IIA cervical carcinoma. Study design: In a retrospective analysis the results of Schauta’s operation have been compared with those of Meigs’ operation in 793 consecutive cases of stage IB or IIA cervical carcinoma. In 201 of them adjuvant radiotherapy was given. A total of 356 patients with stage IB and 76 with stage IIA underwent Schauta’s operation, whereas 268 and 64 patients with stage IB and IIA, respectively, were operated on with Meigs’ procedure. For statistical analysis the Mantel-Haenszel test was used. Results: In stage IB the S-year survival (Kaplan and Meier method) was 8 1% in the Schauta group and 75% in the Meigs group (P < 0.05). The results for stage IIA were 68% and 64%, respectively (difference not significant). In a separate analysis for stage IB and treatment by surgery alone, 5-year survival rates for the 283 in the Schauta group and the I75 in the Meigs group were 83% and 76%, respectively (difference not significant). Conclusion: Schauta’s vaginal hysterectomy showed a high rate of cure for stage IB or IIA cervical cancer. Therefore we conclude that it can be used as an alternative of the Meigs operation in the presence of obesity or elevated surgical risk. Radical hysterectomyfor stage IB adenocarcinomaof the cervix: The University of Miami experience Steren A.; Nguyen H.N.; Averette H.E.; Estape R.; Angioli R.; Donato D.M.; Penalver M.A.; Sevin B.-U. USA GYNECOL ONCOL 1993 48/3 (355-359) The treatment of adenocarcinoma of the cervix has traditionally followed that of squamous cancer. A 25-year review of
Citations from the Literature
resulted in slightly less additive interaction than simultaneous long-term exposure. Pretreatment with S-FU followed by a continuous exposure to MMC was as effective as the simultaneous method, as long as MMC was added within an 8-h interval. Drug schedule dependency was examined, revealing that MMC, as a single agent, is both dose and schedule dependent. The results of these in vitro studies suggest that: (I) exposure to prior chemotherapy does not induce demonstrable pleiotropic drug resistance in these ovarian cancers tested; and (2) combined S-FU and MMC show positive interactions against ovarian cancer cell lines, with optimal scheduling seeming to be long-term simultaneous exposure to both MMC and S-FU. Clirdcal assessment of ~%-CYT-103 immunoscintigraphyin ovarian cancer Surwit E.A.; Childers J.M.; Krag D.N.; Katterhagen J.G.; Gallion H.H.; Waggoner S.; Mann W.J. Jr. USA GYNECOL ONCOL 1993 48/3 (285-292) The ability of “‘In-CYT-103 immunoscintigraphy to aid in the diagnosis of patients with primary or recurrent/residual ovarian cancer was evaluated in a multicenter trial. The “‘lnlabeled irnmunoconjugate of the monoclonal antibody B72.3 was prepared using a site-specific conjugation method. A total of 103 patients received a I mg infusion of “‘In-CYT-103 and subsequently underwent surgery or biopsy. The infusion of “‘In-CYT-103 was well tolerated; only I patient experienced a modest elevation in blood pressure that was likely related to the infusion. “‘In-CYT-103 immunoscintigraphy correctly identified surgically confirmed tumor in 68% of patients with ovarian adenocarcinoma. The sensitivity of “‘InCYT-103 immunoscintigraphy was positively influenced both by the size of the tumor lesion and the tumor TAG-72 antigen expression. The overall sensitivity of “‘InXYT-103 immunoscintigraphy was greater than that of CT imaging (44%). Antibody imaging detected occult disease in 20 of 71 patients with surgically documented ovarian adenocarcinoma; 6 patients being evaluated after initial surgery and chemotherapy had an otherwise negative presurgical workup and a normal CA I25 serum level. The results of this trial also indicate that “‘In-CYT-I03 immunoscintigraphy can contribute to the medical and surgical management of some patients with ovarian cancer. The results of this trial indicate that “‘In-CYT-I03 immunoscintigraphy should be a valuable addition to the presurgical evaluation of patients with suspected persistent or recurrent ovarian cancer. Traasvaginal ultrasonographic characterization of ovarian masses by mesas of color flow-directed Doppler measurements ami a morphologicscoring system Timor-Tritsch I.E.; Lerner J.P.; Monteagudo A.; Santos R. USA AM J OBSTET GYNECOL 1993 16813I (909-913) Objective: The aim of the study was to test the hypothesis that a combination of a previously devised morphologic scoring system and color flow-directed Doppler measurements would afford better discrimination between benign and maligInt J Gynecol Obstet 43
nant ovarian masses. Study design: The scoring system and color flow-directed Doppler measurements for I I5 masses were prospectively analyzed and correlated with histopathologic surgical findings. Results: In 21 masses (18.patients) no flow was obtained. Seventy-eight masses in 70 patients were benign, and I6 masses in I2 patients were malignant. The mean total score for the benign masses was 6.7 and for the malignant masses. I I .7. The resistance index was 0.64 for the benign lesions and 0.39 for the malignant masses (range 0.2 to 0.98). The mean pulsatility index of the benign masses was I. I7 and 0.52 for the malignancies (range 0.2 to 2.6). There were no malignancies in the group with no flow obtained. The sensitivity and specificity of score alone was 94% and 87%, respectively, with a 60% positive predictive value. By means of resistance index or pulsatility index the sensitivity was 94%, the specificity 99% and the positive predictive value 94%. Conclusion: These results suggest that Doppler flow measurements alone and in conjunction with a scoring system help differentiate benign from malignant masses. Schauta-Amreichvaginal hysterectomyand Wertheim-Meigsabdominal hysterectomyin the treatment of cervical cancer: A retrospective analysis Massi G.; Savino L.; Susini T. ITA AM J OBSTET GYNECOL 1993 16813I (928-934) Objective: The aim of the current study was to determine the effectiveness of Schauta’s vaginal hysterectomy in the treatment of stage IB or IIA cervical carcinoma. Study design: In a retrospective analysis the results of Schauta’s operation have been compared with those of Meigs’ operation in 793 consecutive cases of stage IB or IIA cervical carcinoma. In 201 of them adjuvant radiotherapy was given. A total of 356 patients with stage IB and 76 with stage IIA underwent Schauta’s operation, whereas 268 and 64 patients with stage IB and IIA, respectively, were operated on with Meigs’ procedure. For statistical analysis the Mantel-Haenszel test was used. Results: In stage IB the S-year survival (Kaplan and Meier method) was 8 1% in the Schauta group and 75% in the Meigs group (P < 0.05). The results for stage IIA were 68% and 64%, respectively (difference not significant). In a separate analysis for stage IB and treatment by surgery alone, 5-year survival rates for the 283 in the Schauta group and the I75 in the Meigs group were 83% and 76%, respectively (difference not significant). Conclusion: Schauta’s vaginal hysterectomy showed a high rate of cure for stage IB or IIA cervical cancer. Therefore we conclude that it can be used as an alternative of the Meigs operation in the presence of obesity or elevated surgical risk. Radical hysterectomyfor stage IB adenocarcinomaof the cervix: The University of Miami experience Steren A.; Nguyen H.N.; Averette H.E.; Estape R.; Angioli R.; Donato D.M.; Penalver M.A.; Sevin B.-U. USA GYNECOL ONCOL 1993 48/3 (355-359) The treatment of adenocarcinoma of the cervix has traditionally followed that of squamous cancer. A 25-year review of